Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Cherney DZI, DeFronzo RA, Del Prato S, Eckel RH, Filippatos G, Fonarow GC, Fonseca VA, Garvey WT, Giorgino F, Grant PJ, Green JB, Greene SJ, Groop PH, Grunberger G, Jastreboff AM, Jellinger PS, Khunti K, Klein S, Kosiborod MN, Kushner P, Leiter LA, Lepor NE, Mantzoros CS, Mathieu C, Mende CW, Michos ED, Morales J, Plutzky J, Pratley RE, Ray KK, Rossing P, Sattar N, Schwarz PEH, Standl E, Steg PG, Tokgözoğlu L, Tuomilehto J, Umpierrez GE, Valensi P, Weir MR, Wilding J, Wright EE Jr. Handelsman Y, et al. Among authors: bakris gl. Metabolism. 2024 Oct;159:155931. doi: 10.1016/j.metabol.2024.155931. Epub 2024 Jun 7. Metabolism. 2024. PMID: 38852020 Free article.
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, McCullough PA; Conference Participants. House AA, et al. Kidney Int. 2019 Jun;95(6):1304-1317. doi: 10.1016/j.kint.2019.02.022. Epub 2019 Apr 30. Kidney Int. 2019. PMID: 31053387 Free article.
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population.
Tangri N, Ferguson T, Leon SJ, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Farjat AE, Farag YMK, Schloemer P, Lawatscheck R, Rohwedder K, Bakris GL. Tangri N, et al. Among authors: bakris gl. Clin Kidney J. 2024 Mar 6;17(4):sfae052. doi: 10.1093/ckj/sfae052. eCollection 2024 Apr. Clin Kidney J. 2024. PMID: 38650758 Free PMC article.
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, Hadjadj S, Gillard P, Górriz JL, Idorn T, Ji L, Mahaffey KW, Perkovic V, Rasmussen S, Schmieder RE, Pratley RE, Tuttle KR. Mann JFE, et al. Nat Med. 2024 Oct;30(10):2849-2856. doi: 10.1038/s41591-024-03133-0. Epub 2024 Jun 24. Nat Med. 2024. PMID: 38914124 Free PMC article. Clinical Trial.
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
Mahaffey KW, Tuttle KR, Arici M, Baeres FMM, Bakris G, Charytan DM, Cherney DZI, Chernin G, Correa-Rotter R, Gumprecht J, Idorn T, Pugliese G, Rasmussen IKB, Rasmussen S, Rossing P, Sokareva E, Mann JFE, Perkovic V, Pratley R. Mahaffey KW, et al. Eur Heart J. 2024 Aug 30:ehae613. doi: 10.1093/eurheartj/ehae613. Online ahead of print. Eur Heart J. 2024. PMID: 39211948
Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes.
Filippatos G, Anker SD, Bakris GL, Rossing P, Ruilope LM, Coats AJS, von Haehling S, Ponikowski P, Rosano GMC, Brinker M, Farjat AE, Roberts L, Pitt B; FIDELIO‐DKD and FIGARO‐DKD investigators. Filippatos G, et al. Among authors: bakris gl. ESC Heart Fail. 2024 Sep 3. doi: 10.1002/ehf2.14962. Online ahead of print. ESC Heart Fail. 2024. PMID: 39226189 Free article.
Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure.
Patel SS, Raman VK, Zhang S, Deedwania P, Zeng-Treitler Q, Wu WC, Lam PH, Bakris G, Moore H, Heidenreich PA, Rangaswami J, Morgan CJ, Cheng Y, Sheriff HM, Faselis C, Mehta RL, Anker SD, Fonarow GC, Ahmed A. Patel SS, et al. Eur J Heart Fail. 2024 May;26(5):1251-1260. doi: 10.1002/ejhf.3210. Epub 2024 May 3. Eur J Heart Fail. 2024. PMID: 38700246
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.
Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, Sarafidis PA, Tuttle KR, Wanner C, Brinker MD, Dizayee S, Kolkhof P, Schloemer P, Vesterinen P, Perkovic V; FIND-CKD investigators. Heerspink HJL, et al. Among authors: bakris gl. Nephrol Dial Transplant. 2024 Jun 11:gfae132. doi: 10.1093/ndt/gfae132. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 38858818
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
Cardoza K, Kang A, Smyth B, Yi TW, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Wheeler DC, Zhang H, Cannon CP, Perkovic V, Arnott C, Levin A, Mahaffey KW. Cardoza K, et al. Diabetes Obes Metab. 2024 Sep;26(9):3530-3540. doi: 10.1111/dom.15685. Epub 2024 Jun 19. Diabetes Obes Metab. 2024. PMID: 38895796 Clinical Trial.
723 results